Streetbeat News

Earnings

KSPI

Kaspi.kz (KSPI) reported a significant increase in its Q4 earnings and sales, with EPS rising 45% YoY to $9.60 and sales increasing 45% YoY to $1.30 billion.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 9:35 am

LI

Li Auto's stock is trading higher following the announcement of their Q4 financial results, which exceeded expectations. Additionally, the company has provided guidance for Q1 that has positively influenced investor sentiment.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 9:11 am

BH

Biglari Holdings reported its FY 2023 net earnings at $54.95M, a significant improvement from a net loss of $32.03M in the previous year. However, its revenue slightly decreased to $365.32M from $368.23M YoY.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 8:45 am

LI

Li Auto reported Q4 adjusted EPS of $0.30, surpassing the $0.29 estimate, and sales of $5.88B, exceeding the $5.48B estimate. This represents significant year-over-year growth in both earnings and sales.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 8:42 am

LI

Li Auto forecasts Q1 2024 revenue between $4.40B-$4.53B, below the $5.43B estimate, with vehicle deliveries expected to be 100K-103K, marking an increase of 90.2%-95.9% from Q1 2023.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 8:41 am

LI

Li Auto reported a significant increase in vehicle deliveries for Q4 2023, with 131,805 vehicles delivered, marking a 184.6% YoY increase. The full year 2023 saw 376,030 vehicles delivered, up 182.2% from 2022. The company also expanded its retail and service network.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 8:38 am

SNY

Sanofi's Phase 2 trial results for Rilzabrutinib show significant reduction in itch severity and improved disease activity in chronic spontaneous urticaria (CSU) patients. The data, presented at the 2024 AAAAI, supports the initiation of Phase 3 trials for CSU and prurigo nodularis in 2024. Additionally, pivotal Phase 3 and Phase 2 readouts for other conditions are expected in 2024. Rilzabrutinib is highlighted as one of Sanofi's 12 potential blockbuster drugs.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 8:28 am

RHHBY

Roche's Genentech announced positive results from the NIH-sponsored Phase III OUtMATCH study for Xolair, showing it increased tolerance to common food allergens in individuals as young as 1 year. Following this, the U.S. FDA approved Xolair as the first medicine for people with one or more food allergies. This approval is significant given the life-threatening nature of allergic reactions and the high number of food-related anaphylaxis cases treated in U.S. emergency rooms annually.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 8:12 am

BABA

Alibaba Group Holding Ltd co-founder Joe Tsai is optimistic about the company's future, highlighting recent share purchases by founders, a management reshuffle, and plans for future IPOs despite challenges like increased competition and halted IPOs of its logistics and retail arms. Tsai's confidence is backed by a restructuring and a new management team, aiming to reinforce Alibaba's position in China's e-commerce market.

Portfolio Pulse from Benzinga Neuro

February 26, 2024 | 7:53 am

CELU

DPZ

PPC

WDAY

ZM

U.S. stock futures are trading lower, with focus on earnings reports from Domino's Pizza, Celularity Inc., Pilgrim's Pride, Workday, and Zoom Video Communications. Domino's is expected to report increased earnings and revenue. Celularity announced a 1-for-10 reverse stock split, causing a slight share price drop. Pilgrim's Pride is anticipated to report earnings of 40 cents per share. Workday's earnings are projected at $1.47 per share, and Zoom is expected to report earnings of $1.15 per share.

Portfolio Pulse from Avi Kapoor

February 26, 2024 | 7:48 am